Merck & Co., Inc.
MRK- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000310158
In the last 90 days, Merck & Co., Inc. insiders filed 0 open-market purchases and 7 sales; 3,854 institutions reported holding it in 13F filings for Q2 2026, worth $254.3B in total; 4 superinvestors hold it, including Harris Associates (Oakmark) and Fairfax Financial.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Merck & Co., Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 7 filings
- 5 insiders, $30.0M in total
- Insiders trading
- 5
- Net value
- −$30.0M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Merck & Co., Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Guindo Chirfi | EVP, Access, Policy & Comms | 36,613 | Aug 13, 2026 | 8 |
| Zachary Jennifer | EVP, General Counsel | 45,509 | Aug 13, 2026 | 5 |
| DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | 110,167 | Aug 12, 2026 | 6 |
| Maraldo David R. | EVP & Pres. MMD | 18,212 | Aug 7, 2026 | 3 |
| Williams David Michael | EVP,Chief Info&Digital Officer | 31,716 | Aug 7, 2026 | 6 |
| Seidman Christine E | Director | – | Jul 1, 2026 | 5 |
| Karsanbhai Surendralal Lanca | Director | – | Jul 1, 2026 | 2 |
| Coe Mary Ellen | Director | – | Jul 1, 2026 | 5 |
| Russo Patricia F | Director | – | Jun 2, 2026 | 1 |
| Lavizzo-Mourey Risa J | Director | – | Jun 2, 2026 | 1 |
| Glocer Thomas H | Director | – | Jun 2, 2026 | 4 |
| Baker Douglas M Jr | Director | 16,000 | Jun 2, 2026 | 1 |
| Craig Pamela J. | Director | – | Jun 2, 2026 | 1 |
| Thulin Inge G | Director | 2,933 | Jun 2, 2026 | 1 |
| Warden Kathy J | Director | – | Jun 2, 2026 | 1 |
| Rothman Paul | Director | – | Jun 2, 2026 | 1 |
| Mayo Stephen | Director | – | Jun 2, 2026 | 1 |
| Davis Robert M | Chairman, CEO & President | 450,351 | May 7, 2026 | 4 |
| Larson Betty D | EVP, Chief HR Officer | 13,774 | May 7, 2026 | 2 |
| Li Dean Y | Executive VP & President, MRL | 94,431 | May 7, 2026 | 5 |
| Litchfield Caroline | EVP & CFO | 92,301 | May 7, 2026 | 4 |
| Oosthuizen Johannes Jacobus | EVP, Oncology & Int?l | 21,895 | May 7, 2026 | 4 |
| Smart Dalton | SVP Fin. - Global Controller | 9,388 | May 7, 2026 | 5 |
| Foard Brian | EVP, Specialty, Pharma, & ID | – | May 7, 2026 | 1 |
| Chattopadhyay Sanat | Exe V-P & Pres. MMD | 15,347 | May 1, 2026 | 2 |
| Romanelli Joseph | President, Human Health Int?l | 28,739 | Jan 28, 2026 | 1 |
| Downing Cristal N | Chief Comm. & Public Afrs Ofcr | 0 | Nov 12, 2025 | 1 |
| Klobuchar Michael A | EVP - Chief Strategy Officer | 23,621 | May 6, 2024 | 0 |
| Wendell Peter C | Director | – | Mar 29, 2024 | 0 |
| Mizell Steven | EVP, Chief HR Officer | 23,619 | Feb 2, 2024 | 0 |
| Karachun Rita A | Sr. VP Fince-Global Controller | 45,710 | May 5, 2023 | 0 |
| LeCointe-Cephas Lisa | SVP Chief Ethics & Com Officer | 5,142 | May 5, 2023 | 0 |
| Frazier Kenneth C | Executive Chair | 700,653 | Nov 8, 2022 | 0 |
| Garay Arpa | SVP Human Health Global Mktg. | 2,109 | May 5, 2022 | 0 |
| Gerberding Julie L. | EVP, Chief Patient Officer | 48,712 | Feb 28, 2022 | 0 |
| Clyburn Frank | EVP & Pres ? Human Health | 97,095 | Nov 4, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 2, 2021 (view filing) | Oct 29 | 4 days | DeLuca Richard R.EVP&Pres, Merck Animal Heallth | SSale | −135.4K | $87.56 | −$11.9M | −53.7%116.9K after | |
| Nov 2, 2021 (view filing) | Oct 29 | 4 days | Chattopadhyay SanatExe V-P & Pres. MMD | SSale | −24.6K | $87.32 | −$2.15M | −20.9%93.1K after | |
| Nov 2, 2021 (view filing) | Nov 1 | 1 day | Clyburn FrankEVP & Pres ? Human Health | SSale | −39.8K | $87.87 | −$3.49M | −29.1%97.1K after | |
| Nov 3, 2021 (view filing) | Nov 1 | 2 days | Gerberding Julie L.EVP, Chief Patient Officer | SSale | −96.3K | $87.91 | −$8.46M | −71.1%39.2K after | |
| Nov 4, 2021 (view filing) | Nov 3 | 1 day | Karachun Rita ASr. VP Fince-Global Controller | SSale | −25.0K | $88.45 | −$2.21M | −41.1%35.8K after | |
| Nov 5, 2021 (view filing) | Nov 4 | 1 day | Litchfield CarolineEVP & CFO | SSale | −18.3K | $91.00 | −$1.67M | −43.2%24.1K after | |
| Nov 5, 2021 (view filing) | Nov 4 | 1 day | DeLuca Richard R.EVP&Pres, Merck Animal Heallth | SSale | −29.8K | $90.40 | −$2.69M | −20.3%116.9K after | |
| Nov 10, 2021 (view filing) | Nov 9 | 1 day | Frazier Kenneth CExecutive Chair | SSale | −663.9K | $82.27 | −$54.6M | −53.1%586.8K after | 2 lots |
| Nov 1, 2022 (view filing) | Oct 28 | 4 days | Zachary JenniferEVP, General Counsel | SSale | −165.3K | $99.38 | −$16.4M | −81.3%38.0K after | 2 lots |
| Nov 1, 2022 (view filing) | Oct 28 | 4 days | Oosthuizen Johannes JacobusPresident, U.S. Market | SSale | −3.63K | $100.21 | −$364.1K | −25.0%10.9K after | |
| Nov 1, 2022 (view filing) | Oct 28 | 4 days | Mizell StevenEVP, Chief HR Officer | SSale | −25.0K | $99.63 | −$2.49M | −43.7%32.1K after | 2 lots |
| Nov 1, 2022 (view filing) | Oct 28 | 4 days | Karachun Rita ASr. VP Fince-Global Controller | SSale | −32.0K | $100.34 | −$3.21M | −43.8%41.1K after | |
| Nov 1, 2022 (view filing) | Oct 28-31 | 4 days | Frazier Kenneth CExecutive Chair | SSale | −867.1K | $100.44 | −$87.1M | −55.1%706.3K after | 5 lots |
| Nov 1, 2022 (view filing) | Oct 28 | 4 days | DeLuca Richard R.EVP&Pres, Merck Animal Heallth | SSale | −164.6K | $100.26 | −$16.5M | −54.6%137.0K after | |
| Nov 1, 2022 (view filing) | Oct 28 | 4 days | Chattopadhyay SanatExe V-P & Pres. MMD | SSale | −100.3K | $100.10 | −$10.0M | −68.7%45.6K after | |
| Nov 3, 2022 (view filing) | Nov 1-2 | 2 days | Frazier Kenneth CExecutive Chair | SSale | −600.0K | $99.86 | −$59.9M | −46.1%700.7K after | 5 lots |
| Nov 7, 2022 (view filing) | Nov 3-4 | 4 days | Frazier Kenneth CExecutive Chair | SSale | −470.0K | $98.66 | −$46.4M | −40.1%700.7K after | 4 lots |
| Nov 7, 2022 (view filing) | Nov 7 | Same day | Oosthuizen Johannes JacobusPresident, U.S. Market | SSale | −45.6K | $99.47 | −$4.53M | −71.1%18.5K after | |
| Nov 8, 2022 (view filing) | Nov 7 | 1 day | Frazier Kenneth CExecutive Chair | SSale | −235.8K | $99.55 | −$23.5M | −25.2%700.7K after | 3 lots |
| Nov 10, 2022 (view filing) | Nov 9 | 1 day | Davis Robert MCEO & President | SSale | −167.6K | $102.44 | −$17.2M | −40.4%247.6K after | 3 lots |
| Nov 10, 2022 (view filing) | Nov 9 | 1 day | Oosthuizen Johannes JacobusPresident, U.S. Market | SSale | −1.79K | $103.21 | −$185.3K | −9.7%16.7K after | |
| Nov 10, 2022 (view filing) | Nov 8-10 | 2 days | Mizell StevenEVP, Chief HR Officer | SSale | −35.0K | $101.18 | −$3.54M | −52.1%32.1K after | 2 lots |
| Jan 11, 2023 (view filing) | Jan 9 | 2 days | Chattopadhyay SanatExe V-P & Pres. MMD | SSale | −84.0K | $112.29 | −$9.43M | −74.0%29.5K after | 5 lots |
| Feb 6, 2023 (view filing) | Feb 3 | 3 days | Zachary JenniferEVP, General Counsel | SSale | −75.4K | $103.17 | −$7.78M | −58.3%53.9K after | |
| Feb 8, 2023 (view filing) | Feb 6 | 2 days | Mizell StevenEVP, Chief HR Officer | SSale | −4.44K | $104.25 | −$462.5K | −10.0%39.9K after | |
| Feb 10, 2023 (view filing) | Feb 9 | 1 day | Mizell StevenEVP, Chief HR Officer | SSale | −5.00K | $107.00 | −$535.0K | −12.5%34.9K after | |
| Feb 14, 2023 (view filing) | Feb 13 | 1 day | Mizell StevenEVP, Chief HR Officer | SSale | −1.81K | $109.10 | −$198.0K | −5.2%33.1K after | |
| Feb 16, 2023 (view filing) | Feb 15 | 1 day | Romanelli JosephPresident, Human Health Int?l | SSale | −5.00K | $108.22 | −$541.1K | −19.8%20.3K after | |
| Apr 14, 2023 (view filing) | Apr 13 | 1 day | Chattopadhyay SanatExe V-P & Pres. MMD | SSale | −134.1K | $115.07 | −$15.4M | −100.0%0 after | 2 lots |
| Apr 28, 2023 (view filing) | Apr 28 | Same day | Davis Robert MChairman, CEO & President | SSale | −143.3K | $114.93 | −$16.5M | −34.5%271.8K after | |
| May 2, 2023 (view filing) | Apr 28-May 1 | 4 days | DeLuca Richard R.EVP&Pres, Merck Animal Heallth | SSale | −141.6K | $115.55 | −$16.4M | −47.8%154.5K after | 2 lots |
| May 3, 2023 (view filing) | May 2 | 1 day | Williams David MichaelEVP,Chief Info&Digital Officer | SSale | −7.51K | $116.82 | −$877.2K | −40.4%11.1K after | |
| May 5, 2023 (view filing) | May 4 | 1 day | Karachun Rita ASr. VP Fince-Global Controller | SSale | −15.9K | $117.53 | −$1.87M | −25.8%45.7K after | |
| May 5, 2023 (view filing) | May 4 | 1 day | Zachary JenniferEVP, General Counsel | SSale | −19.1K | $117.59 | −$2.25M | −35.3%35.1K after | |
| May 5, 2023 (view filing) | May 3 | 2 days | Mizell StevenEVP, Chief HR Officer | SSale | −53.4K | $119.01 | −$6.36M | −62.8%31.7K after | 4 lots10b5-1 |
| Jun 30, 2023 (view filing) | Dec 2, 2022 | 210 daysLate | Romanelli JosephPresident, Human Health Int?l | PPurchase | +59 | $109.67 | +$6.47K | New position59 after | |
| Jun 30, 2023 (view filing) | Dec 5, 2022-Apr 26, 2023 | 207 daysLate | Romanelli JosephPresident, Human Health Int?l | PPurchase | +350 | $108.19 | +$37.9K | +1.7%20.6K after | 7 lots |
| Jun 30, 2023 (view filing) | Mar 24 | 98 daysLate | Romanelli JosephPresident, Human Health Int?l | SSale | −35 | $104.65 | −$3.66K | −0.2%20.6K after | |
| Aug 3, 2023 (view filing) | Aug 2 | 1 day | Romanelli JosephPresident, Human Health Int?l | SSale | −30 | $107.37 | −$3.22K | −0.1%20.6K after | |
| Aug 3, 2023 (view filing) | Aug 2 | 1 day | Romanelli JosephPresident, Human Health Int?l | SSale | −59 | $107.37 | −$6.33K | −100.0%0 after | |
| Aug 4, 2023 (view filing) | Aug 3 | 1 day | Mizell StevenEVP, Chief HR Officer | SSale | −4.50K | $105.49 | −$474.7K | −14.2%27.2K after | |
| Aug 15, 2023 (view filing) | Aug 14 | 1 day | Mizell StevenEVP, Chief HR Officer | SSale | −4.25K | $109.01 | −$463.3K | −15.6%22.9K after | |
| Nov 9, 2023 (view filing) | Nov 8 | 1 day | DeLuca Richard R.EVP&Pres, Merck Animal Heallth | SSale | −43.8K | $105.03 | −$4.60M | −28.2%111.8K after | |
| Nov 13, 2023 (view filing) | Nov 9 | 4 days | Oosthuizen Johannes JacobusPresident, U.S. Market | SSale | −2.08K | $102.38 | −$213.1K | −10.3%18.2K after | |
| Feb 2, 2024 (view filing) | Feb 2 | Same day | Zachary JenniferEVP, General Counsel | SSale | −49.5K | $126.97 | −$6.28M | −63.0%29.1K after | |
| Feb 2, 2024 (view filing) | Feb 2 | Same day | Mizell StevenEVP, Chief HR Officer | SSale | −50.7K | $126.65 | −$6.42M | −68.2%23.6K after | |
| Feb 5, 2024 (view filing) | Feb 2 | 3 days | Oosthuizen Johannes JacobusPresident, U.S. Market | SSale | −19.0K | $127.18 | −$2.41M | −44.8%23.3K after | |
| Feb 8, 2024 (view filing) | Feb 7 | 1 day | Williams David MichaelEVP,Chief Info&Digital Officer | SSale | −1.45K | $127.57 | −$185.1K | −6.8%19.8K after | |
| Feb 12, 2024 (view filing) | Feb 9 | 3 days | Li Dean YExecutive VP & President, MRL | SSale | −14.7K | $125.50 | −$1.85M | −24.1%46.2K after | |
| Feb 14, 2024 (view filing) | Feb 13 | 1 day | Romanelli JosephPresident, Human Health Int?l | SSale | −1.00K | $124.89 | −$124.9K | −4.9%19.6K after |